Supriya Lifescience Limited (NSE:SUPRIYA)

Market Cap	56.06B
Revenue (ttm)	6.71B
Net Income (ttm)	1.75B
Shares Out	80.48M
EPS (ttm)	21.66
PE Ratio	32.16
Forward PE	31.22
Dividend	0.80 (0.11%)
Ex-Dividend Date	Sep 20, 2024

Volume	262,731
Average Volume	261,246
Open	709.40
Previous Close	709.45
Day's Range	691.35 - 713.00
52-Week Range	330.00 - 842.00
Beta	0.19
RSI	53.69
Earnings Date	May 23, 2025

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer det...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 448
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUPRIYA

Financial Performance

In 2023, Supriya Lifescience's revenue was 5.70 billion, an increase of 23.74% compared to the previous year's 4.61 billion. Earnings were 1.19 billion, an increase of 32.56%.